Vimarsana
Biggest News Aggregation in the World

Page 5 - Scientific Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Presentations Today - Breaking & Trending Today

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Vimarsana News

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

12.04.2023 - SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) - Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral ... Seite 1

Aligos Therapeutics to Present Data from Chronic Hepatitis - Vimarsana News

Aligos Therapeutics to Present Data from Chronic Hepatitis

SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference - Vimarsana News

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

SOUTH SAN FRANCISCO, Calif., March 29, 2023 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in... | March 29, 2023

Concert Pharmaceuticals medicine help improve scalp hair regrowth in Alopecia Areata reveal data - Vimarsana News

Concert Pharmaceuticals medicine help improve scalp hair regrowth in Alopecia Areata reveal data

The significant improvements in scalp hair regrowth were achieved at 24 weeks for patients taking 8 mg twice-daily and 12 mg twice-daily doses of deuruxolitinib.

Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata - Vimarsana News

Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata

/PRNewswire/ -- Concert Pharmaceuticals ("Concert"), a company recently acquired by Sun Pharmaceutical Industries Limited (including its subsidiaries and/or...